Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
Focused
on advancing
the next wave
of medicine for
inflammatory
diseases
KIT inhibition of
mast cells
mast cells
holds the potential to achieve the clinical efficacy needed for broad symptomatic relief across a range of inflammatory disorders.
More Science
Our lead product candidate, THB335,
is expected to enter clinical trials during the second quarter of 2024.
More Programs
DO YOU HAVE WHAT IT TAKES TO GO THRD?
We’re looking for driven, big picture thinkers who are passionate about making medicines and building a great company.
More Careers